BIO-TECHNE Corp TECH
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
5/9
Piotroski F — financial health
5.89
Altman Z″ — distress risk · safe
68.7%
Dividend payout · stretched
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.2B | $73.4M | $790.3M | $256.6M | $1.9B |
| 2024 | $1.2B | $168.1M | $769.7M | $236.1M | $2.1B |
| 2023 | $1.1B | $285.3M | $769.8M | $216.1M | $2.0B |
| 2022 | $1.1B | $272.1M | $756.5M | $280.4M | $1.7B |
| 2021 | $931.0M | $140.4M | $632.9M | $307.9M | $1.6B |
| 2020 | $738.7M | $229.3M | $483.2M | $153.5M | $1.4B |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 5.89 (safe)
- Working capital / assets 0.169
- Retained earnings / assets 0.417
- EBIT / assets 0.04
- Equity / liabilities 3.003
Source: SEC EDGAR filings · CIK 0000842023 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.